171 related articles for article (PubMed ID: 19693537)
1. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo.
Jin C; Li H; He Y; He M; Bai L; Cao Y; Song W; Dou K
J Cancer Res Clin Oncol; 2010 Feb; 136(2):267-74. PubMed ID: 19693537
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of localized ultrasound-targeted microbubble destruction with doxorubicin liposomes in H22 mouse hepatocellular carcinoma model.
Zhu F; Jiang Y; Luo F; Li P
J Drug Target; 2015 May; 23(4):323-34. PubMed ID: 25609362
[TBL] [Abstract][Full Text] [Related]
3. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
4. Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma.
Mao CY; Hua HJ; Chen P; Yu DC; Cao J; Teng LS
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):282-7. PubMed ID: 19502169
[TBL] [Abstract][Full Text] [Related]
5. A novel anti-alpha-fetoprotein single-chain variable fragment displays anti-tumor effects in HepG2 cells as a single agent or in combination with paclitaxel.
Ji X; Shen Y; Sun H; Gao X
Tumour Biol; 2016 Aug; 37(8):10085-96. PubMed ID: 26820129
[TBL] [Abstract][Full Text] [Related]
6. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma.
Zhu D; Wu S; Hu C; Chen Z; Wang H; Fan F; Qin Y; Wang C; Sun H; Leng X; Kong D; Zhang L
Acta Biomater; 2017 Aug; 58():399-412. PubMed ID: 28627436
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.
Zhou Q; Ching AK; Leung WK; Szeto CY; Ho SM; Chan PK; Yuan YF; Lai PB; Yeo W; Wong N
Int J Oncol; 2011 Mar; 38(3):721-31. PubMed ID: 21240457
[TBL] [Abstract][Full Text] [Related]
8. In-vitro and in-vivo investigation of amygdalin, metformin, and combination of both against doxorubicin on hepatocellular carcinoma.
Mamdouh AM; Khodeer DM; Tantawy MA; Moustafa YM
Life Sci; 2021 Nov; 285():119961. PubMed ID: 34536497
[TBL] [Abstract][Full Text] [Related]
9. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
[TBL] [Abstract][Full Text] [Related]
10. Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo.
Hossain MA; Kim DH; Jang JY; Kang YJ; Yoon JH; Moon JO; Chung HY; Kim GY; Choi YH; Copple BL; Kim ND
Int J Oncol; 2012 May; 40(5):1636-42. PubMed ID: 22322725
[TBL] [Abstract][Full Text] [Related]
11. Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma.
Kang HG; Wang BZ; Zhang J; Liu MR; Li YX
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):197-203. PubMed ID: 27863926
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.
Kwak MS; Yu SJ; Yoon JH; Lee SH; Lee SM; Lee JH; Kim YJ; Lee HS; Kim CY
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2037-45. PubMed ID: 25989942
[TBL] [Abstract][Full Text] [Related]
13. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
[TBL] [Abstract][Full Text] [Related]
14. Association between reversal of multidrug resistance by methyl jasmonate and P-glycoprotein ATPase activity in hepatocellular carcinoma.
Wang CF; Wang YQ; Huang FZ; Nie WP; Liu XY; Jiang XZ
J Int Med Res; 2013 Aug; 41(4):964-74. PubMed ID: 23867448
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo conditional sensitization of hepatocellular carcinoma cells to TNF-induced apoptosis by taxol.
Minero VG; De Stefanis D; Costelli P; Baccino FM; Bonelli G
Cell Cycle; 2015; 14(7):1090-102. PubMed ID: 25564714
[TBL] [Abstract][Full Text] [Related]
16. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
Fujimoto S; Chikazawa H
Jpn J Cancer Res; 1998 Dec; 89(12):1343-51. PubMed ID: 10081496
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of α-Mangostin and sorafenib in hepatocellular carcinoma: New insights into α-mangostin cytotoxicity.
Wang TT; Hong YF; Chen ZH; Wu DH; Li Y; Wu XY; Huang HQ; Zhang Q; Jia CC
Biochem Biophys Res Commun; 2021 Jun; 558():14-21. PubMed ID: 33894673
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect of Doxorubicin and tacrolimus (FK506) on hepatocellular carcinoma cell lines.
Capone F; Guerriero E; Sorice A; Colonna G; Storti G; Pagliuca J; Castello G; Costantini S
ScientificWorldJournal; 2014; 2014():450390. PubMed ID: 24701168
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia as a target for drug combination therapy of liver cancer.
Bowyer C; Lewis AL; Lloyd AW; Phillips GJ; Macfarlane WM
Anticancer Drugs; 2017 Aug; 28(7):771-780. PubMed ID: 28542038
[TBL] [Abstract][Full Text] [Related]
20. Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin.
Xiong W; Ren ZG; Qiu SJ; Sun HC; Wang L; Liu BB; Li QS; Zhang W; Zhu XD; Liu L; Wang WQ; Tang ZY
BMC Cancer; 2010 May; 10():219. PubMed ID: 20487542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
